ARID1A and cholangiocarcinoma: Also, Ogiwara et al. (2019) summarized that ARID1A is mutated in about 46% of ovarian clear cell carcinomas, 43% of uterine corpus endometrial carcinomas, 33% of gastric carcinomas, 30% of ovarian endometrioid carcinomas, 28% of bladder carcinomas, 27% of cholangiocarcinomas, 15% of pancreatic carcinomas, 12% of lung adenocarcinomas, and 10% of CRC.